AURA
NASDAQ HealthcareAura Biosciences, Inc. - Common Stock
Biotechnology
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision therapies to treat solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. It focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer. The company was incorporated in 2009 and is headquartered in Boston, Massachusetts.
๐ Market Data
| Price | $7.01 |
|---|---|
| Volume | 205,314 |
| Market Cap | 450.04M |
| Beta | 0.350 |
| RSI (14-Day) | 52.2 |
| 200-Day MA | $6.15 |
| 50-Day MA | $6.50 |
| 52-Week High | $7.68 |
| 52-Week Low | $4.34 |
| Forward P/E | -3.45 |
| Price / Book | 3.26 |
๐ฏ Investment Strategy Scores
AURA scores across each investment strategy. Higher is better for that strategy's goals.
๐ Strategy Interpretation
Best fit: ๐ฐ Dividend Daddy (47/100) โ this strategy High dividend yield + low volatility.
Lowest fit among scored strategies: ๐ Institutional Whale (12/100). No single score is a buy or sell signal โ use multiple lenses together. Learn how to read these scores โ
๐ Learn More
Indicators on this page
Educational articles
Find AURA in your text
Paste any article, transcript, or post โ the tool will extract AURA and every other hidden ticker.
Disclaimer: This data is for educational and entertainment purposes only and does not constitute financial advice. Market data may be delayed. Always do your own research before making investment decisions.
Data last updated: 2026-05-01.